Skip to main content


for people ages 6–18 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.

Official Title

Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis


Plaque Psoriasis children psoriasis treatment adolescents


You can join if…

Open to people ages 6–18

  • Have a diagnosis of moderate-to-severe plaque-type psoriasis for at least 6 months prior to baseline as determined by the investigator.
  • Have PASI score ≥12 and a sPGA ≥3 and body surface area involvement ≥10% at screening and baseline.
  • Are candidates for phototherapy or systemic treatment or considered by the investigator as not adequately controlled by topical therapies.
  • Male subjects agree to use a reliable method of birth control during the study.
  • Female subjects are women of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks following the last dose of investigational product,whichever is longer.
  • Both the child or adolescent and a parent or legal guardian are able to understand and fully participate in the activities of the clinical study and sign their assent and consent, respectively.
  • All immunizations are up-to-date in agreement with current immunization guidelines, in the opinion of the investigator.

You CAN'T join if...

  • Have pustular, erythrodermic, and/or guttate forms of psoriasis.
  • Have drug-induced psoriasis.
  • Have clinical and/or laboratory evidence of untreated latent or active tuberculosis(TB).
  • Participants with a documented history of immune deficiency syndrome.
  • Have any other active or recent infection, including chronic or localized infections,within 4 weeks of baseline.
  • Subjects with a known history of malignancy, lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease,such as lymphadenopathy and/or splenomegaly.
  • Have used any therapeutic agent targeted at reducing interleukin-17.
  • Have received other therapies within the specified timeframes below:
  • adalimumab and infliximab 60 days, abatacept 90 days, anakinra 7 days, or any other biologic disease-modifying antirheumatic drug 5 half-lives prior to baseline.
  • systemic therapy for psoriasis and psoriatic arthritis (PsA) (other than above,eg, methotrexate, cyclosporine), phototherapy (eg, photochemotherapy [psoralen plus ultraviolet A]) in the previous 4 weeks.


  • Stanford University Hospital not yet accepting patients
    Palo Alto, California, 94304, United States


accepting new patients
Start Date
Completion Date
Eli Lilly and Company
Phase 3
Lead Scientist
Tina Bhutani
Study Type
Last Updated
July 1, 2017
I’m interested in this study!